摘要
二甲双胍(MET)为2型糖尿病(T2MD)治疗的一线用药,糖尿病患癌风险高,而MET可减少T2MD患癌风险、协同治疗癌症。子宫内膜癌(EC)是女性癌症死亡的六大病因之一,MET通过抑制EC细胞增殖、迁移,诱导EC细胞凋亡和自噬及外泌体的改变延缓EC进展;联合辅助治疗可增强药物对EC细胞的敏感性、减少复发、降低总病死率等。文章对MET在EC防治中应用的最新临床及基础研究进行综述。
Metformin(MET)is a first-line drug for type 2 diabetes mellitus(T2MD).Diabetes is associated with a high risk of cancer.However,MET can reduce the risk and exert synergistic effect on cancer in T2MD patients.Endometrial cancer(EC)is one of the six major causes of female cancer deaths.MET can delay EC progression through inhibiting cell proliferation and migration,inducing apoptosis and autophagy,and altering exosomes.The combined adjuvant therapy can enhance the sensitivity of drugs to EC cells and reduce the recurrence and overall mortality.This article reviews the latest clinical and basic research on the application of MET in the prevention and treatment of EC.
作者
时曼莹
余鹏
赖晓阳
SHI Man-ying;YU Peng;LAI Xiao-yang(Department of Endocrinology,the Second Affiliatel Hospital of Nanchang University,Nanchang 330006,China)
出处
《南昌大学学报（医学版）》
2021年第3期84-87,共4页
Journal of Nanchang University：Medical Sciences
基金
江西省科技厅青年科学基金(S2019QNZD2B0350)。
关键词
二甲双胍
子宫内膜癌
自噬
外泌体
耐药性
综述
metformin
endometrial cancer
autophagy
exosomes
drug resistance
review
